SpringWorks Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SpringWorks Therapeutics wird ein Gewinn- und Umsatzwachstum von 47.9% bzw. 45.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 47% pro Jahr wachsen soll.

Wichtige Informationen

47.9%

Wachstumsrate der Gewinne

47.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	45.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

May 11

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

May 03

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

Apr 25

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

Apr 19

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15

SpringWorks shows durable effect for neurofibroma therapy with long-term data

Jun 15

SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma

Jun 07

We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

May 31

SpringWorks Therapeutics EPS misses by $0.11

May 06

SpringWorks Therapeutics announces C-level promotions

Dec 15

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SWTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	639	-70	N/A	N/A	2
12/31/2025	318	-241	-117	-115	7
12/31/2024	139	-334	-80	-79	7
3/31/2024	26	-339	-245	-240	N/A
12/31/2023	5	-325	-230	-223	N/A
9/30/2023	N/A	-305	-226	-214	N/A
6/30/2023	N/A	-298	-195	-183	N/A
3/31/2023	N/A	-289	-185	-175	N/A
12/31/2022	N/A	-277	-172	-162	N/A
9/30/2022	N/A	-259	-164	-154	N/A
6/30/2022	N/A	-228	-168	-161	N/A
3/31/2022	N/A	-206	-160	-155	N/A
12/31/2021	N/A	-174	-130	-128	N/A
9/30/2021	35	-107	-67	-66	N/A
6/30/2021	35	-87	-55	-54	N/A
3/31/2021	35	-60	-37	-37	N/A
12/31/2020	35	-46	-33	-32	N/A
9/30/2020	N/A	-73	-64	-63	N/A
6/30/2020	N/A	-68	-60	-60	N/A
3/31/2020	N/A	-62	-57	-57	N/A
12/31/2019	N/A	-51	-48	-47	N/A
9/30/2019	N/A	-41	-35	-34	N/A
6/30/2019	N/A	-29	-31	-30	N/A
3/31/2019	N/A	-18	-20	-19	N/A
12/31/2018	N/A	-18	-14	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SWTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SWTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SWTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SWTXDie Einnahmen des Unternehmens (45.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: SWTXDie Einnahmen des Unternehmens (45.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SWTX in 3 Jahren voraussichtlich hoch sein wird

SpringWorks Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 54%, EPS downgraded

Consensus revenue estimates increase by 21%, EPS downgraded

Consensus revenue estimates increase by 33%, EPS downgraded

Price target increased by 7.7% to US$67.53

Price target increased by 11% to US$61.86

Consensus revenue estimates decrease by 13%

Recent updates

Chief Operating Officer notifies of intention to sell stock

SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues

Consensus revenue estimates increase by 54%, EPS downgraded

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear

SpringWorks Therapeutics, Inc. to Report Q1, 2024 Results on May 02, 2024

SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners

SpringWorks Therapeutics, Inc., Annual General Meeting, May 16, 2024

Consensus revenue estimates increase by 21%, EPS downgraded

SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Consensus revenue estimates increase by 33%, EPS downgraded

Price target increased by 7.7% to US$67.53

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 11% to US$61.86

SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer

Consensus revenue estimates decrease by 13%

SpringWorks Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999982 million.

New minor risk - Shareholder dilution

SpringWorks Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Consensus revenue estimates decrease by 29%

Price target increased by 15% to US$54.83

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

New minor risk - Share price stability

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

Consensus revenue estimates decrease by 26%

SpringWorks Therapeutics, Inc. Announces Positive Topline Results from the Phase 2B ReNeu Trial of Mirdametinib in NF1-PN

Consensus revenue estimates decrease by 12%

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

SpringWorks Therapeutics, Inc. Appoints Tai-An Lin as Chief Scientific Officer

Consensus revenue estimates fall by 81%

Price target decreased by 9.8% to US$50.50

SpringWorks Therapeutics, Inc.(NasdaqGS:SWTX) dropped from Russell Small Cap Comp Value Index

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

SpringWorks Therapeutics, Inc. Announces PDUFA Date Extension for Nirogacestat NDA

Insufficient new directors

Consensus revenue estimates increase by 125%

Springworks Therapeutics, Inc. Announces Data from Two Collaboration-Sponsored Clinical Studies Evaluating Nirogacestat in Combination with B-Cell Maturation Agent in Patients with Relapsed or Refractory Multiple Myeloma

Consensus revenue estimates decrease by 85%

Price target decreased by 12% to US$57.00

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Springworks Therapeutics Completes Submission of New Drug Application to the Fda for Nirogacestat for the Treatment of Adults with Desmoid Tumors

Price target decreased to US$64.50

Price target decreased to US$69.80

Price target decreased to US$69.80

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Springworks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

SpringWorks Therapeutics, Inc. Announces Resignation of Michael Burgess as the Head of Research and Development

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

SpringWorks Therapeutics, Inc. announced that it expects to receive $224.349775 million in funding from EcoR1 Capital, LLC, Boxer Capital LLC, The Invus Group, LLC, Deerfield Management Company, L.P. Series C, Perceptive Advisors LLC and other investor

SpringWorks drops 21% as Allogene drops lead asset in combination study

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Sizing Up SpringWorks Therapeutics

SpringWorks Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Price target decreased to US$95.40

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

SpringWorks Therapeutics, Inc., Annual General Meeting, May 19, 2022

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Springworks Therapeutics Announces Clinical Collaboration with Abbvie to Evaluate Nirogacestat in Combination with Abbv-383 in Patients with Relapsed or Refractory Multiple Myeloma

Springworks Therapeutics, Inc. Announces Dosing of First Patient in Phase 1B/2 Trial Evaluating Nirogacestat in Combination with Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Springworks Therapeutics Announces Full Enrollment of Phase 2B ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with Nf1-Associated Plexiform Neurofibromas

CEO & Director notifies of intention to sell stock

Chief Development Officer exercised options and sold US$537k worth of stock

Chief Development Officer exercised options and sold US$537k worth of stock

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Chief People Officer exercised options to buy US$159k worth of stock.

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations